ALLAN J. MORRISON Jr., M.D., M.S.; CAROL V. FREER, M.D.; C. LYNN POOLE, R.N.P.; DANA O. JOHNSTON, R.N.P.; FREDERIC WESTERVELT Jr., M.D.; DAVID E. NORMANSELL, Ph.D.; RICHARD P. WENZEL, M.D.
More than 13 000 cases of the acquired immunodeficiency syndrome (AIDS) have been reported. The identification of the human T-lymphotropic virus type III (HTLV-III) as the causative agent has led to an increased understanding of the likely modes of transmission as well as the identification of persons at risk for infection. Currently, about 80 000 patients require regular dialysis in the United States (1). Patients requiring such dialysis would appear to be at high risk for infection with HTLV-III because of their having received multiple transfusions before the initiation of nationwide screening of blood products for HTLV-III antibody (2, 3).
MORRISON AJ, FREER CV, POOLE CL, JOHNSTON DO, WESTERVELT F, NORMANSELL DE, et al. Prevalence of Human T-Lymphotropic Virus Type III Antibodies Among Patients in Dialysis Programs at a University Hospital. Ann Intern Med. ;104:805–807. doi: 10.7326/0003-4819-104-6-805
Download citation file:
Published: Ann Intern Med. 1986;104(6):805-807.
HIV, Hospital Medicine, Infectious Disease, Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use